Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAB-B7-H4
- Development stage
- Preclinical
- Lead developer
- Himalaya Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CAB-B7-H4 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Himalaya Therapeutics. It is designed to target B7-H4 (also known as VTCN1), a transmembrane protein that is highly overexpressed in various solid tumors—including breast, ovarian, and prostate cancers—while maintaining limited expression in normal tissues. The therapeutic mechanism involves the antibody component binding specifically to B7-H4-expressing tumor cells, followed by internalization and the delivery of a cytotoxic payload to induce cell death. Currently listed as a 'clinic ready' asset, CAB-B7-H4 is positioned for transition into early-phase clinical trials for multiple oncology indications.
- Other names
- B7-H4 ADCB-7-H4 ADCB 7-H4 ADCHimalaya Therapeutics B7-H4 ADC
02
Targets
VTCN1 (V-set domain containing T cell activation inhibitor 1)
Beyond the preview
Go deeper on CAB-B7-H4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAB-B7-H4.